COMP <GO>
PHIO vs BFRG // EV/EBITDA & P/E VALUATION
Phio Pharmaceuticals Corp. (NASDAQ) VS. Bullfrog AI Holdings Inc. (NASDAQ) • 15-METRIC TALLY: PHIO 1
— BFRG 2
■ METRIC PARITY
LAST: $0.86 (-5.91%) • MKT CAP: $10.0M
valuation
—
LAST: $0.51 (+3.88%) • MKT CAP: $9.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHIO VS. BFRG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PHIO | BFRG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 18.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | BFRG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.2 | 43.4 | -6.22 | BFRG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.0M | $9.4M | $639.0K | PHIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PHIO REV | BFRG REV | PHIO GROSS % | BFRG GROSS % | PHIO FCF | BFRG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $116.7K | — | 18.8% | -$8.0M | -$5.5M |
| FY 2024 | $0 | $0 | — | — | -$7.1M | -$5.6M |
| FY 2023 | $0 | $65.0K | — | — | -$10.7M | -$6.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHIO // BETA —
BFRG // BETA —